When compared with placebo or other therapies, GLP-1 agonists were associated with an increased risk of biliary disease [23]: Overall biliary disease: RR 1.37(95% CI 1.231.52) Cholelithiasis: RR 1.27 (95% CI 1.101.47) Cholecystitis: RR 1.36 (95% CI 1.141.62) Mechanisms: Reduced gallbladder motility Rapid weight loss increased cholesterol saturation and gallstone formation
Given their increasing use across the UK, questions have emerged regarding potential effects on sexual function, particularly erectile dysfunction (ED) in men
You may notice: Nausea, often when starting or increasing the dose A reduced appetite, which supports weight loss Mild stomach discomfort, constipation, or diarrhea Temporary fatigue during early treatment Eating smaller meals, avoiding high-fat foods, and staying hydrated help minimize these effects
The bottleneck, as that report summarised plainly for pharmaceutical executives and investors, "is no longer discovery but manufacturing." Lock in long-term contracts with established peptide manufacturers
These medications are effective in reducing the chances of major adverse cardiovascular events, such as cardiovascular death , non-fatal heart attacks , and strokes
